Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJoseph Gligorov, Luis Matamala, Hamdy A. Azim et al.|European Journal of Cancer|2017Cited by 47
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium studyEunyoung Kang, Ashley Weir, Nicola S. Meagher et al.|Cancer|2022Cited by 46
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Alexander Hein, Joshua Millstein et al.|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2021Cited by 23